StockWatch
·

Bajaj Healthcare Ltd Q2 FY27 Results

BAJAJHCAREQ2 FY27 Results
Filing
Result:Very Good· Market: Flat#Margin squeeze#One-off gain

Outlook: Optimistic · Guidance: Raised

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue175.906.2%18.9%
Total Income176.796.2%18.2%
Expenditure158.325.6%18.5%
PBT18.4812.3%15.8%
Net Profit14.092.9%26.9%
OPM17.74%0.38pp0.48pp
NPM7.97%0.26pp0.54pp
EPS4.273.4%8.1%
View full financials

Revenue growth of 18.9% YoY clears the top of FY27 guidance, but adjusted PAT growth of 15.5% (stripping the discontinued-ops one-off) and a slight OPM dip (18.2%→17.7%) point to healthy, above-average but not standout core performance.

BAJAJ HEALTHCARE · Q2 FY-2027 · THE VERDICT

Beat Guidance, But API Softness and Capex Doubling Are the Real Reads

Q2 revenue surged 18.9% YoY and comfortably beat full-year guidance, but formulation strength masks a sharp slowdown in domestic API. Management has doubled its capex bet and set an audacious ₹1,000 Cr revenue target for FY29 — execution risk is real.

27 Oct 2026 · 6 min read
Q2 Revenue

₹175.9 Cr

+18.9% YoY vs FY27 guidance 10–15%

Q2 PAT

₹14.1 Cr

+26.9% YoY, NPM 8.0% (up from 7.5% prior Q2)

EBITDA

₹32.1 Cr

Margin 18.2%, +40 bps QoQ from 17.8%

Bajaj Healthcare's Q2 result reads strong on the surface — revenue and profit both beat the company's own full-year guidance by a comfortable margin. But the composition tells a more complex story. A formulation surge driven by the Genrx integration masks a domestic API business that has slowed to single-digit growth, a direct consequence of the Gulf pricing crisis and inventory buildup that management had to absorb. Margin held, but the growth trajectory split into two speeds: one fast (formulations, exports), one slow (domestic API, the legacy core). And management has just doubled its capex bet to fund a ₹1,000 Crore revenue target by FY29 — a vision that depends on three major facility launches over the next two years, each with execution risk.

Where the quarter's growth came from

Q2 FY27 Revenue, ₹ Cr
026.7353.4680.1971.6Domestic API62.6Export API41.7Formulations
Formulations surged 82% YoY post-Genrx approval, now 24% of quarterly revenue. Domestic API growth stalled at 10.1% YoY due to Gulf pricing pressure; export API strength at 28.5% YoY carries the beat.

Of the ₹175.9 Cr in Q2 revenue, formulations contributed ₹41.7 Cr, a 78.8% year-on-year surge that reflects the Genrx Pharmaceuticals acquisition NCLT approval in Q1 FY27. That segment alone grew ₹18.8 Cr in absolute terms — more than half of the quarter's total growth. Export APIs added another ₹17.5 Cr in absolute growth (at 28.5% YoY), driven by DMF filings, Magnesium L-Threonate (~11–12% of turnover), and international approvals. Domestic API, by contrast, grew only ₹6.4 Cr in absolute terms (+10.1% YoY) — a clear deceleration from the 15–20% range seen in prior quarters. Management attributes this to the West Asia supply-chain crisis, which forced inventory buildups at both the company and its domestic customers, dampening natural demand cycles.

Margin held despite the headwind

The quarter's EBITDA margin of 18.2% is notable not for where it is, but for the fact that it is there at all. Domestic API carries the company's lowest margins; a quarter where it contributed only 10.1% growth (vs. export's 28.5% and formulations' 82%) should ordinarily see margin compression. Instead, margin expanded 40 basis points quarter-on-quarter (from 17.8% in Q1) and stayed within management's 18–20% FY27 guidance band. The fix: formulations and exports are higher-margin segments. The trade-off: this mix shift is a window into the fundamental challenge — the company is progressively exiting a margin-light, volume-heavy domestic API business and moving toward specialty (peptides, oncology), exports, and formulations. That's healthy long-term. But in the near term, it means the company must execute three major facility launches (peptide plant March 2027, oncology API Q2 FY28, Genrx Manjusar integration ongoing) without stumbling.

What changed on this call

Three material shifts from prior guidance:

  • FY27 capex raised to ₹65–80 Cr from prior ₹40–50 Cr — a 60% increase to fund peptide plant acceleration, oncology API setup, Nashik formulation plant, and R&D expansion.

  • FY29 revenue target set at ₹900–1,000 Cr with EBITDA margin 18–21% — a new multi-year anchor. Implies ₹1,000 Cr is the company's 3-year north star.

  • Formulation mix target raised to 50–55% of revenue by FY27–28, vs. today's 10–11%. Domestic API expected to shrink to 45–50% mix — a strategic rebalancing away from commodity pricing pressure.

In addition, management disclosed that Cenobamate (the anti-seizure drug launched in September 2026 with 8 marketing partners) is expected to grow to 50–100 partner companies by contract maturity, but refused to quantify revenue for the next 2 years, framing it only as 'difficult but growing'. This hedging, combined with the capex escalation, signals that management is betting on optionality — if Cenobamate ramps faster than expected, the peptide and oncology facilities can feed export growth; if it ramps slower, the company still has the Genrx synergies and backward-integration upside to chase the ₹1,000 Cr target.

Management's key claims — what holds up

Validation of on-call claims against delivered result

Q2 revenue ₹175.9 Cr, +18.9% YoY beats 10–15% FY27 guidance

Supported

Delivered: ₹175.9 Cr, YoY +18.9%. H1 FY27 ₹341.5 Cr vs ₹296.8 Cr prior = +14.9%.

PAT grew 26.9% YoY to ₹14.1 Cr; NPM improved to 8.0%

Supported

Delivered: PAT ₹14.1 Cr, +26.9% YoY (vs ₹11.1 Cr prior Q2), NPM 8.0% vs 7.5% prior Q2.

Formulations revenue ₹41.7 Cr, +82% YoY; Genrx integration on track

Supported

Delivered: ₹41.7 Cr vs ₹22.9 Cr prior year = +82%. NCLT approval Q1 FY27 enables Manjusar facility transition.

EBITDA margin 18.2%, within FY27 guidance of 18–20%

Supported

Delivered: ₹32.1 Cr EBITDA on ₹175.9 Cr revenue = 18.2% margin, +40 bps QoQ from 17.8%.

FY27 capex raised to ₹65–80 Cr from prior ₹40–50 Cr

Supported

CFO Rohan Parekh confirmed: 'Total expected capex for FY27 will be around INR65 crores to INR80 crores.'

On track for FY27 10–15% revenue growth

Supported

H1 FY27 ₹341.5 Cr vs ₹296.8 Cr = 14.9% growth. Q2 alone at 18.9%. Full-year trajectory confirmed.

The debate

The bull-bear ledger

Positives and warnings side by side
  • Beat FY27 10–15% revenue guidance; H1 at 14.9%, Q2 at 18.9%

  • PAT growth (26.9% YoY) exceeds revenue growth — operating leverage intact

  • Formulations +82% YoY, now 24% of revenue; reduces commodity API dependency

  • Export API +28.5% YoY driven by DMF filings (110+) and international approvals

  • EBITDA margin held at 18.2% despite domestic API slowdown and inventory buildup

  • Domestic API growth stalled at 10.1% YoY — structural pricing pressure, not cyclical

  • Capex doubled (₹40–50 Cr → ₹65–80 Cr for FY27); execution risk increases if facilities slip

  • Cenobamate launch unquantified for 2 years; management hedging on ramp timing

  • West Asia crisis forcing inventory buildup; working capital headwind now, risk extends

  • FY29 ₹1,000 Cr target credible but contingent on 3 facility launches over 24 months

Risks ranked by holder concern

What could derail the thesis, ordered by impact on a holder

Domestic API pricing collapse extends beyond Q2

High

Still 48% of Q2 revenue. If Gulf crisis forces sustained price cuts (vs. inventory-driven slowdown), margins could compress 200–300 bps. No hedging visible.

Facility execution delays (peptide March 2027, oncology Q2 FY28)

High

FY29 ₹1,000 Cr target depends entirely on these launches. 6-month delay to peptide or 8-month delay to oncology API deflates cumulative revenue by ₹100–200 Cr.

Cenobamate adoption slower than 50–100 partner target

Medium

Management refused to quantify revenue for next 2 years; if secondary sales slow or doctor uptake stalls, formulation growth forecast falters, reducing offset to API weakness.

Genrx Manjusar facility transition stalled or capacity-constrained

Medium

₹41.7 Cr formulations revenue (+82% YoY) now depends on seamless migration from Baroda to Manjusar. Integration delays could reverse Q2's formulation momentum.

Working capital tightens from West Asia inventory buildup

Medium

Q2 OCF only ₹15 Cr on ₹14.1 Cr PAT (OCF/PAT = 1.1x) signals inventory absorption. If inventory normalizes slowly, cash generation remains weak despite strong PAT.

Interest rate rise and macro stress hit demand and receivables

Low

Management noted unpredictability; receivables improved 145→135 days but macro slowdown could extend cycles again. Domestic API exposure (48% of revenue) is most sensitive.

How the street is positioned — and what it means

The stock closed at ₹307.45 on 2026-10-26, trading below all major moving averages (SMA20 ₹327.13, SMA50 ₹328.07, SMA200 ₹331.30) and down 58.73% from its all-time high of ₹745. The 52-week range of ₹272.35–₹490 frames a 12.89% recovery off the lows — which suggests the market found support at ₹272, but hasn't re-engaged the upside after Q2's beat. RSI of 36.2 is neutral, neither oversold nor overbought; volume trend is normal.

On the ownership side, FII have quietly added 21 basis points (2.19% in Q1 FY27 vs 1.98% in Q4 FY26), the largest move in their holding in at least 6 quarters. But this is still a thin 2.19% FII stake — foreign flows have not rushed in. DII, by contrast, trimmed 99 basis points (1.92% in Q1 FY27 vs 2.91% in Q4 FY26), suggesting domestic institutional appetite has cooled. Promoters remain firmly anchored at 58.59%, up 30 basis points — a positive signal, but not a material insider buying momentum.

Bulk and block deals over the past 6 months show mostly financial institutions and trading firms in motion (JUNOMONETA, MICROCURVES, NK SECURITIES, JUMP TRADING, QE SECURITIES). No promoter or insider-linked selling is flagged. The absence of insider buying into the beaten-down stock (despite a beat to guidance) is worth noting; management confidence is high in tone, but capital allocation is restrained.

The combined picture: the market has repriced Bajaj Healthcare down 58% from peak, but hasn't rewarded the Q2 beat with material day-1 momentum. That suggests the market is waiting for either (a) proof that domestic API recovery is underway, or (b) visibility into facility execution and Cenobamate ramp. FII inching in suggests some value recognition, but the thin ownership means a reversal in flow would be fragile. The stock's position below all moving averages and well off the 52-week low suggests buyers and sellers are at an impasse.

What to watch next

The next three quarters will answer these concrete questions
  • 1 · Domestic API recovery timing

    H2 FY27 (Oct–Mar) will show whether the 10.1% YoY growth in Q2 was a trough or a trend. If West Asia inventory normalization begins and pricing stabilizes, Q3 and Q4 can show sequential recovery. If domestic API stalls further, the company's commodity exposure remains a drag and margin is at risk.

  • 2 · Peptide facility delivery and early revenue

    Operational readiness by March 2027 is critical (only 6 months away as of Q2). Early evidence of customer on-boarding and pilot orders would validate the ₹170–100 Cr first-year revenue assumption. Any delay signals execution risk and defers FY29 ₹1,000 Cr visibility.

  • 3 · Cenobamate secondary sales trajectory

    Management said repeat orders from the 8 launch partners are 'moving well' but refused to quantify. Q3 and Q4 FY27 commentary will reveal whether ramp is slow (single-digit ₹ Cr), steady (₹10–20 Cr run rate), or accelerating. This de-risks or re-risks the FY29 formulation upside.

The analyst verdict

This is not a step-change quarter — it's steady execution on a credible multi-year plan. The beat to guidance is real and earned (formulations surging, exports growing 28.5%, margin held despite API softness). The capex doubling is aggressive but justified by the ₹1,000 Cr target and the time-limited window to scale peptide and oncology capacity. But the repricing (down 58% from peak) reflects very real execution and macro risks that holders should not dismiss. For value-oriented investors with a 24-month horizon, the risk-reward tilts toward the thesis if domestic API stabilizes in H2 FY27 and facilities are on track by Q3 FY27. For shorter-term traders, the stock's position below moving averages and thin FII ownership suggest volatility remains high until one of the three watch items above moves positive. Steady execution, not a bet; the company has earned the benefit of the doubt with its track record, but the market is right to ask for proof on facility launches and Cenobamate adoption.

Informational and educational content only. Not investment advice.